Showing results (461-470 of 4,122) with videos related to
Sort By:
Pageof 413
Human Gene Therapy|May 17, 2012
Transcription activator-like effector proteins induce the expression of the frataxin geneJacques P Tremblay, Pierre Chapdelaine, Zoé Coulombe, et al.Human Gene Therapy|June 2, 2012
Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responsesNatalie A Hutnick, Devin J F Myles, Bernadette Ferraro, et al.Human Gene Therapy|August 7, 2018
Locally Targeting the IL-17/IL-17RA Axis Reduced Tumor Growth in a Murine B16F10 Melanoma ModelYa-Shan Chen, Tse-Hung Huang, Chao-Lin Liu, et al.Human Gene Therapy|August 22, 2018
One Group's Historical Reflections on DNA Vaccine DevelopmentEllen F Fynan, Shan Lu, Harriet L RobinsonHuman Gene Therapy|August 1, 2018
A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 VirusesSarah T C Elliott, Amelia A Keaton, Jacqueline D Chu, et al.Human Gene Therapy|September 12, 2018
Gene Therapy for HemoglobinopathiesMarina Cavazzana, Fulvio MavilioHuman Gene Therapy|April 21, 1999
Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer modelsP C Emtage, Y Wan, M Hitt, et al.Human Gene Therapy|February 18, 1999
In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene deliveryC M Ahmed, B J Sugarman, D E Johnson, et al.Human Gene Therapy|February 18, 1999
Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant RevJ A Ragheb, L Couture, C Mullen, et al.Human Gene Therapy|February 18, 1999
Generation of retroviral vector for clinical studies using transient transfectionS Yang, R Delgado, S R King, et al.Pageof 413